

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application.

1-10. (canceled)

11. (previously presented) An isolated human IKK- γ nucleic acid molecule encoding a polypeptide having at least 90% amino acid identity with SEQ ID NO:2, wherein said polypeptide has one or more biological activities of a full-length IKK- γ polypeptide.

12. (canceled)

13. (previously presented) An isolated human IKK- γ nucleic acid molecule comprising a nucleotide sequence encoding amino acid sequence SEQ ID NO:2.

14. (previously presented) The isolated human IKK- γ nucleic acid molecule of Claim 13, comprising nucleotides 149 to 1408 of SEQ ID NO:1.

15. (previously presented) The isolated human IKK- γ nucleic acid molecule of Claim 13, comprising SEQ ID NO:1.

16-29. (canceled)

30. (currently amended) ~~A human origin~~ An isolated antisense polynucleotide, comprising a nucleotide sequence complementary to nucleotides 149 to 1408 SEQ ID NO:1.

31. (previously presented) The isolated human IKK- γ nucleic acid molecule of Claim 11, wherein said one or more biological activities of a full-length IKK- γ polypeptide comprise interaction with IKK- α/β in cells.

32. (previously presented) The isolated human IKK- γ nucleic acid molecule of Claim 11, wherein said one or more biological activities of a full-length IKK- γ polypeptide comprise IKK- β binding activity.

33. (previously presented) The isolated human IKK- γ nucleic acid molecule of Claim 11, wherein said one or more biological activities of a full-length IKK- γ polypeptide comprise IKK- α binding activity.

34. (previously presented) The isolated human IKK- γ nucleic acid molecule of Claim 11, wherein said one or more biological activities of a full-length IKK- γ polypeptide comprise dimerization or trimerization activity.